|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Metastatic Colorectal Cancer | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Colorectal Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Colonic Diseases | |||||
| Digestive System Diseases | |||||
| Digestive System Neoplasms | |||||
| Gastrointestinal Diseases | |||||
| Gastrointestinal Neoplasms | |||||
| Intestinal Diseases | |||||
| Intestinal Neoplasms | |||||
| Neoplasms | |||||
| Neoplasms by Site | |||||
| Rectal Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| GDC-0449 | |||||
| placebo | |||||
| bevacizumab | |||||
| chemotherapy | |||||
| 5 | More general drug interventions related to this trial | ||||
| Angiogenesis Inhibitors | |||||
| Angiogenesis Modulating Agents | |||||
| Antineoplastic Agents | |||||
| Growth Inhibitors | |||||
| Growth Substances | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| Genentech | |||||